Concepedia

Publication | Open Access

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

DOIFull Paper Access

39

Citations

27

References

2014

Year

Jian Zhang, Junning Cao, Jin Li, Yifan Zhang, Zhiyu Chen, Wei Peng, Si Sun, Naiqing Zhao, Jiachen Wang, Dafang Zhong,
Journal of Hematology & Oncology

Abstract

Based on the DLT and PK profile, the RP2D was defined as 1000 mg TID with evidence of preliminary anti-tumor activity. Further studies are recommended.

References

YearCitations

Page 1